These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 9702843)

  • 1. A pharmacokinetic study of intravenous itraconazole followed by oral administration of itraconazole capsules in patients with advanced human immunodeficiency virus infection.
    Zhou H; Goldman M; Wu J; Woestenborghs R; Hassell AE; Lee P; Baruch A; Pesco-Koplowitz L; Borum J; Wheat LJ
    J Clin Pharmacol; 1998 Jul; 38(7):593-602. PubMed ID: 9702843
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics of intravenous itraconazole followed by itraconazole oral solution in patients with human immunodeficiency virus infection.
    Zhao Q; Zhou H; Pesco-Koplowitz L
    J Clin Pharmacol; 2001 Dec; 41(12):1319-28. PubMed ID: 11762559
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Concentrations in plasma and safety of 7 days of intravenous itraconazole followed by 2 weeks of oral itraconazole solution in patients in intensive care units.
    Vandewoude K; Vogelaers D; Decruyenaere J; Jaqmin P; De Beule K; Van Peer A; Woestenborghs R; Groen K; Colardyn F
    Antimicrob Agents Chemother; 1997 Dec; 41(12):2714-8. PubMed ID: 9420044
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Food interaction and steady-state pharmacokinetics of itraconazole oral solution in healthy volunteers.
    Barone JA; Moskovitz BL; Guarnieri J; Hassell AE; Colaizzi JL; Bierman RH; Jessen L
    Pharmacotherapy; 1998; 18(2):295-301. PubMed ID: 9545149
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics and safety of a 7-day administration of intravenous itraconazole followed by a 14-day administration of itraconazole oral solution in patients with hematologic malignancy.
    Boogaerts MA; Maertens J; Van Der Geest R; Bosly A; Michaux JM; Van Hoof A; Cleeren M; Wostenborghs R; De Beule K
    Antimicrob Agents Chemother; 2001 Mar; 45(3):981-5. PubMed ID: 11181397
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Single-dose pharmacokinetics of intravenous itraconazole and hydroxypropyl-beta-cyclodextrin in infants, children, and adolescents.
    Abdel-Rahman SM; Jacobs RF; Massarella J; Kauffman RE; Bradley JS; Kimko HC; Kearns GL; Shalayda K; Curtin C; Maldonado SD; Blumer JL
    Antimicrob Agents Chemother; 2007 Aug; 51(8):2668-73. PubMed ID: 17517842
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Influence of grapefruit juice on the systemic availability of itraconazole oral solution in healthy adult volunteers.
    Gubbins PO; McConnell SA; Gurley BJ; Fincher TK; Franks AM; Williams DK; Penzak SR; Saccente M
    Pharmacotherapy; 2004 Apr; 24(4):460-7. PubMed ID: 15098799
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Itraconazole trough concentrations in antifungal prophylaxis with six different dosing regimens using hydroxypropyl-beta-cyclodextrin oral solution or coated-pellet capsules.
    Glasmacher A; Hahn C; Molitor E; Marklein G; Sauerbruch T; Schmidt-Wolf IG
    Mycoses; 1999; 42(11-12):591-600. PubMed ID: 10680434
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics of intravenous itraconazole in stable hemodialysis patients.
    Mohr JF; Finkel KW; Rex JH; Rodriguez JR; Leitz GJ; Ostrosky-Zeichner L
    Antimicrob Agents Chemother; 2004 Aug; 48(8):3151-3. PubMed ID: 15273137
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics of itraconazole after intravenous and oral dosing of itraconazole-cyclodextrin formulations.
    Buchanan CM; Buchanan NL; Edgar KJ; Klein S; Little JL; Ramsey MG; Ruble KM; Wacher VJ; Wempe MF
    J Pharm Sci; 2007 Nov; 96(11):3100-16. PubMed ID: 17712849
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enhanced bioavailability of itraconazole in hydroxypropyl-beta-cyclodextrin solution versus capsules in healthy volunteers.
    Barone JA; Moskovitz BL; Guarnieri J; Hassell AE; Colaizzi JL; Bierman RH; Jessen L
    Antimicrob Agents Chemother; 1998 Jul; 42(7):1862-5. PubMed ID: 9661037
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Linking the concentrations of itraconazole and 2-hydroxypropyl-β-cyclodextrin in human intestinal fluids after oral intake of Sporanox
    Berben P; Stappaerts J; Vink MJA; Domínguez-Vega E; Somsen GW; Brouwers J; Augustijns P
    Eur J Pharm Biopharm; 2018 Nov; 132():231-236. PubMed ID: 29959034
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics of itraconazole (oral solution) in two groups of human immunodeficiency virus-infected adults with oral candidiasis.
    Reynes J; Bazin C; Ajana F; Datry A; Le Moing JP; Chwetzoff E; Levron JC
    Antimicrob Agents Chemother; 1997 Nov; 41(11):2554-8. PubMed ID: 9371367
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Itraconazole disposition after single oral and intravenous and multiple oral dosing in healthy cats.
    Boothe DM; Herring I; Calvin J; Way N; Dvorak J
    Am J Vet Res; 1997 Aug; 58(8):872-7. PubMed ID: 9256973
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intravenous itraconazole followed by oral itraconazole for the treatment of amphotericin-B-refractory invasive pulmonary aspergillosis.
    Caillot D
    Acta Haematol; 2003; 109(3):111-8. PubMed ID: 12714819
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety, pharmacokinetics, and pharmacodynamics of cyclodextrin itraconazole in pediatric patients with oropharyngeal candidiasis.
    Groll AH; Wood L; Roden M; Mickiene D; Chiou CC; Townley E; Dad L; Piscitelli SC; Walsh TJ
    Antimicrob Agents Chemother; 2002 Aug; 46(8):2554-63. PubMed ID: 12121932
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Itraconazole solution: higher serum drug concentrations and better clinical response rates than the capsule formulation in acquired immunodeficiency syndrome patients with candidosis.
    Cartledge JD; Midgely J; Gazzard BG
    J Clin Pathol; 1997 Jun; 50(6):477-80. PubMed ID: 9378812
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Repeated-dose pharmacokinetics of an oral solution of itraconazole in infants and children.
    de Repentigny L; Ratelle J; Leclerc JM; Cornu G; Sokal EM; Jacqmin P; De Beule K
    Antimicrob Agents Chemother; 1998 Feb; 42(2):404-8. PubMed ID: 9527794
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intravenous itraconazole followed by oral itraconazole in the treatment of invasive pulmonary aspergillosis in patients with hematologic malignancies, chronic granulomatous disease, or AIDS.
    Caillot D; Bassaris H; McGeer A; Arthur C; Prentice HG; Seifert W; De Beule K
    Clin Infect Dis; 2001 Oct; 33(8):e83-90. PubMed ID: 11550120
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics of itraconazole and hydroxyitraconazole in healthy subjects after single and multiple doses of a novel formulation.
    Mouton JW; van Peer A; de Beule K; Van Vliet A; Donnelly JP; Soons PA
    Antimicrob Agents Chemother; 2006 Dec; 50(12):4096-102. PubMed ID: 16982783
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.